There has been a dramatic increase in requests for coeliac disease (CD) serological screening using immunoglobulin (Ig)A tissue transglutaminase antibodies (IgA-tTG). Recently, the UK National Institute for Health and Care Excellence has revised its guidance, recommending that total IgA should also be measured in all samples. This is justified, as false-negative results may occur with IgA deficiency. However, implementation of this guidance will incur considerable expense. Tests that measure IgA-tTG antibodies can detect IgA deficiency, indicated by low background signal. This provides an opportunity to identify samples containing IgA 0Á2g/l, obviating the need for unselected IgA measurement. We investigated the feasibility of this approach in two centres that use the EliA TM Celikey TM assay or QUANTA Lite V R enzyme-linked immunosorbent assay to quantify IgA-tTG antibodies. In both cases, total IgA correlated strongly with background IgA-tTG assay signal. Using the Celikey TM assay, a threshold of < 17Á5 response units achieved 100% sensitivity (95% confidence intervals 79Á4-100%) for detection of IgA 0Á2g/l, circumventing the need for IgA testing in > 99% of sera. A similar principle was demonstrated for the QUANTA Lite V R assay, whereby a threshold optical density of < 0Á0265 also achieved 100% sensitivity (95% confidence intervals 78Á2-100%) for IgA 0Á2 g/l, avoiding unnecessary IgA testing in 67% of cases. These data suggest that CD screening tests can identify samples reliably containing low IgA in a real-life setting, obviating the need for blanket testing. However, this approach requires careful individualized validation, given the divergent efficiency with which assays identify samples containing low IgA.
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Introduction
It has been hypothesized that fewer than 20% of patients with coeliac disease (CD) have been identified worldwide [1, 2] . Increasing awareness of this issue has led to a striking increase in immunoglobulin (Ig)A tissue transglutaminase (IgA-tTG) antibody test requests [3] . Although rates of diagnosis have improved [4, 5] , poorly focused testing is a recognized problem [3] . To assist clinicians, the UK National Institute for Health and Care Excellence (NICE) issued Clinical Guideline 68 (2009) -Recognition and Assessment of Coeliac Disease (https://www.nice.org.uk/ guidance; accessed 16 March 2010). However, the rates of test positivity remained unchanged and are little better than would be expected from blind screening of the general population [3, 6] . In 2015, NICE guidance was updated to recommend that IgA should be measured in all serum-based CD screening requests [7] , aligning with other guidance [5, [8] [9] [10] . This is justified on the basis that false-negative results are expected with selective IgA deficiency (sIgAD), requiring alternative testing approaches. In sIgAD, IgA is undetectable (< 0Á07 g/l) at age 4 years or above, without secondary cause or abnormality of other immunoglobulin isotypes [11, 12] . The prevalence of sIgAD is one in 600 [13] , although up to 3% of CD patients may be affected [5, [14] [15] [16] .
Partial IgA deficiency (pIgAD) is a much more common occurrence and is characterized by detectable but subnormal IgA levels [17] . However, pIgAD rarely compromises the performance of the IgA tTG test [16, 18] . To mitigate risk further, the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) recommends that non-IgA-based CD screening tests should be used for samples containing IgA 0Á2 g/l [8] .
A requirement for IgA testing of all CD screens would add significant stress to overburdened health services. One proposed workaround exploits the known ability of IgAtTG analytical platforms to identify SIgAD [19] [20] [21] [22] [23] [24] [25] . Extrapolating from this, we hypothesized that algorithms that identify sera robustly containing IgA 0Á2 g/l would obviate the need for blanket IgA measurement. Here, we tested the feasibility of this approach in two centres where distinct CD screening tests are performed.
Materials and methods

Detection of IgA tTG antibodies
Barnet Hospital receives approximately 10 000 requests for CD screening per annum. Testing was undertaken using the EliA TM Celikey TM assay (Thermo Fisher Scientific, Waltham, MA, USA) run on a Phadia 250 fully automated platform (Thermo Fisher Scientific), as recommended by the manufacturers. In brief, wells are precoated with recombinant human tTG. After addition of serum and washing, bound IgA-tTg antibody is detected using beta galactosidaseconjugated anti-IgA secondary antibodies. Next, 4-methylumbelliferyl-b-D-galactoside substrate is added, which yields a fluorescent product. After stopping the reaction with sodium carbonate, fluorescence emission is expressed as response units (RU), which are generated automatically by the software from a six-point calibration curve. Eastbourne Hospital receives approximately 8500 requests for CD screening annually. Samples were analysed using the QUANTA Lite V R R h-tTG IgA enzyme-linked immunosorbent assay (ELISA) (Inova Diagnostics, San Diego, CA, USA) on a DS2
V R automated ELISA platform (Dynex Technologies, Worthing, UK), as recommended by the manufacturers. The principle underlying assay performance is similar to the Celikey TM assay, except that the secondary antibody is peroxidase-conjugated. After the addition of 3,3',5,5' tetramethylbenzidine substrate, a blue product is generated. The reaction is stopped using sulphuric acid, which yields a yellow end-point colour that is read at 450 nm. Data are expressed as optical density (OD) units, which are generated automatically by the software from a five-point calibration curve. In both cases, assay readout (RU or OD units, respectively) is converted to arbitrary units of IgA-tTG antibodies, given that there are no international standards for IgA-tTG antibodies.
Measurement of serum IgA
Serum IgA at Barnet Hospital was measured using an immunoturbidimetric assay run on an Architect ci8200 (Abbott Diagnostics, Lake Forest, IL, USA). At Eastbourne Hospital, the Cobas Tina-quant IgA Gen. 2 assay (Roche Diagnostics, Mannheim, Germany) was used.
Quality assurance and quality control
Both laboratories participate in United Kingdom National External Quality Assessment Service (UK NEQAS) schemes for all assays performed. For each assay, internal quality control was performed throughout using independently sourced third-party quality control material.
Statistical analysis
The The median age of patients tested at both sites was compared using the Mann-Whitney Utest, which was performed using SPSS. Receiver operating characteristic (ROC) analysis was performed using Graphpad Prism version 6.0g. In all cases, two-sided P-values are shown. Ethical approval was not required for this analysis and all data were anonymized fully throughout the analysis. Age-related reference ranges for serum IgA were taken from Milford Ward et al. [26] .
Results
Detection of low IgA containing samples using the EliA TM Celikey TM assay
The relationship between serum IgA and RU generated using the EliA TM Celikey TM assay was investigated in a data set comprising 367 consecutive and age-unselected tests in which RU was below 100 (median age 22 years; Fig. 1a) . A strong correlation between these two parameters was observed (Kendall's tau-b 0Á496, P 5 0). There was also a significant, albeit weak, correlation between RU and age (Kendall's tau-b 0Á19, P 5 1Á2 3 10
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), in keeping with the age-dependent nature of the normal range for IgA [26] .
Next, we explored whether background signal reported by these assays could be used to identify all samples containing IgA 0Á2 g/l, a level below which IgA-tTG testing becomes less robust [8] . A receiver operating characteristic (ROC) curve was plotted that employs RU as determined in the EliA TM Celikey TM assay to discriminate between samples containing IgA 0Á2 g/l or > 0Á2 g/l (Fig. 1b) . Close to perfect test performance is indicated by the area under the curve of 0Á99. Using an RU threshold of 17Á5, 100% sensitivity (95% confidence intervals 79Á4-100%) was achieved for all samples containing IgA 0Á2 g/l. At these low RU levels, a strong correlation between RU and serum IgA was noted (Kendall's tau-b 0Á95, P 5 0; Supporting information, Fig. S1 ). Samples with an RU < 17Á5 contained IgA 0Á2 g/l in 57% of cases (Supporting information, Fig. S1 ).
Validation of the threshold to detect low IgA using the EliA TM Celikey TM assay
Next, we tested this algorithm using a prospectively collected validation data set comprising 100 consecutive tests in which RU was < 50 (Fig. 1c) . In this unselected sample (median age 11Á5 years; Fig. 1c ), a strong correlation was observed once again between serum IgA and RU (Kendall's tau-b 0Á504; P 5 0; Fig. 1c ). All samples containing IgA 0Á2 g/l fell below the threshold RU of 17Á5.
Detection of samples containing low IgA using QUANTA Lite V R IgA-tTG ELISA
To test the applicability of this strategy to an alternative IgA-tTG assay, we undertook a similar analysis using the QUANTA Lite V R IgA-tTG ELISA. All sera submitted for four randomly selected and sequential CD testing runs (n 5 264; median age 33 years) were analysed. Correlation between IgA and optical density units was strong (Kendall's tau-b 0Á653 (P 5 0); Fig. 2a) .
ROC curve analysis indicated that a threshold OD of 0Á0265 or below allowed the detection of all samples containing IgA 0Á2 g/l (95% confidence intervals 78Á2-100%; Fig. 2b ). However, only 15 of 87 (17Á2%) samples with an OD below the threshold contained IgA 0Á2 g/l (Supporting information, Fig. S2 ). The correlation between serum IgA and OD levels below this threshold was also significant (Kendall's tau-b 0Á346; P 5 4Á6 3 10 26 ).
Validation of the threshold to detect low IgA using QUANTA Lite V R IgA-tTG ELISA
To validate the ability of the QUANTA Lite V R ELISA to discriminate IgA 0Á2 g/l and > 0Á2 g/l, a consecutive ageunselected series of 103 sera in which OD was at or above the threshold (0Á0265-0Á04 OD units) were analysed for IgA. Although correlation between OD units and IgA was weaker (Kendall's tau-b 0Á169; P 5 0Á014; Fig. 2c ), no sample contained IgA 0Á2 g/l (range 5 0Á54-2Á86 g/l).
Discussion
This study presents independent audits that investigated whether two IgA-tTG antibody assays could robustly identify sera containing IgA 0Á2 g/l. This threshold was selected because ESPGHAN recommends that non-IgA based tests should be used in this setting [8] . Although low levels of IgA may influence RU or OD units in an unpredictable manner (particularly given that it is a rare event), the approach proposed here could eliminate the need for total IgA testing in the majority of cases. Using the Celikey TM assay, most samples with RU < 17Á5 contained low IgA. Given that < 1% of samples tested yield an RU below this threshold, IgA testing could be avoided in more than 99% of cases. Similarly, identification of a safe threshold for identifying low IgA levels using the QUANTA Lite V R ELISA could obviate the need for measurement of total IgA in 67% of cases.
If tests requesting patterns seen at these district general hospitals are extrapolated nationally, it is estimated that 1-1Á2 million requests for CD screening are made annually. A serum IgA test has been costed fully at £30 (http://www. thepathlab.co.uk/; accessed 22 February 2017), meaning that implementation of updated NICE guidance would cost £30 million per annum. If our findings are confirmed, virtually all these funds could be recouped by implementation of a threshold RU on the Celikey TM assay. However, laboratories need to carefully validate and verify such algorithms locally. Alternatively, laboratories may offer combined IgG-based testing (e.g. IgG deamidated gliadin peptide antibodies). These also perform well as CD screening tests when IgA is deficient, although this would represent a more costly approach.
Our study has a number of limitations. First, we have demonstrated the applicability of this method to two of more than 25 assays available to measure IgA-tTG antibodies. Secondly, comparison between the performance of these assays is not possible, given the different numbers of samples tested with different age distributions of patients. Thirdly, the possibility of inadvertent ascertainment bias should be considered. Although our analysis was undertaken with unselected serum samples, it is noteworthy that an outlier population in which low RU accompanied higher IgA levels (Celikey TM assay) was more apparent in the training data set compared to the validation set. Ascertainment bias is a well-recognized issue in many studies of CD screening serology [27] .
The need for blanket IgA testing of coeliac screens has been questioned, as it rarely unmasks a diagnosis of CD and may lead to unnecessary biopsy [28, 29] . It also increases workload and test turnaround time and increases the negative predictive value of the IgA-tTG test (from 99Á8 to 99Á9%) marginally, but at a cost of more than $32 605 per false-negative test missed [30] . We also encountered issues with confused users seeking advice on how to investigate borderline high or low IgA results that had not been requested in the first instance and which were of dubious clinical significance.
NICE responded to these points, arguing that application of IgA-tTG tests to identify sIgAD represents the incorrect use of these assays [31] . NICE speculated that false-positive results might arise due to rheumatoid factor or haemolysis. No evidence was presented in support of these concerns, and we did not identify any such issues in these audits. NICE highlighted the potential benefit of detecting immunodeficiency using blanket IgA testing, an incident so rare as to warrant reporting [32] . We view this as an inappropriate use of CD screening testing. Blind screening is rarely cost-effective and the most common immunodeficiency that would be detected is sIgAD, for which screening cannot be justified on the basis of costbenefit analysis. The updated NICE guideline reverses their previous recommendation to check for IgA deficiency 'if the laboratory detects a low or very low optical density on IgA-tTG test' . Consideration should be given to reinstatement of this earlier recommendation. Such an approach can be adapted to maintain consistency with ESPGHAN guidance [8] , but must be dependent upon the ability of the laboratory to set a robust threshold that identifies all low IgA samples. 
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